Literature DB >> 27790498

Massive Pulmonary Embolism in a Patient Using Warfarin at Therapeutic Dose.

Sunnetcioglu Aysel1, Esen Ramazan2, Arisoy Ahmet3.   

Abstract

Warfarin sodium is commonly used for the prevention and treatment of thromboembolism. The efficacy of warfarin therapy depends on maintaining the International Normalised Ratio (INR) within the target range for the indication. A 56-year-old male presented to the emergency department with dyspnea and chest pain, together with pain and swelling in both legs. The patient had been taking warfarin at the therapeutic dose since having undergone an aortic valve replacement four years ago. His vital signs were an arterial pressure of 60/30 heart rate of 138 beats per minute, respiratory rate of 30 per minute and oxygen saturation of 60%. Computed tomography of the chest revealed thrombosis of the right pulmonary artery and its segmental branches. On investigating the aetiology of the venous thromboembolism, the level of Antithrombin III (AT III) activity was found to be at 37% (normal range, 80-120%).

Entities:  

Keywords:  Antithrombin III; Thromboembolism; Vitamin K antagonists

Year:  2016        PMID: 27790498      PMCID: PMC5071998          DOI: 10.7860/JCDR/2016/18609.8510

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  7 in total

Review 1.  Upper-extremity deep vein thrombosis.

Authors:  Hylton V Joffe; Samuel Z Goldhaber
Journal:  Circulation       Date:  2002-10-01       Impact factor: 29.690

2.  Inflammation and hemostasis biomarkers and cardiovascular risk in the elderly: the Cardiovascular Health Study.

Authors:  N A Zakai; R Katz; N S Jenny; B M Psaty; A P Reiner; S M Schwartz; M Cushman
Journal:  J Thromb Haemost       Date:  2007-06       Impact factor: 5.824

3.  A study of Protein S antigen levels in 3788 healthy volunteers: influence of age, sex and hormone use, and estimate for prevalence of deficiency state.

Authors:  A C Dykes; I D Walker; A D McMahon; S I Islam; R C Tait
Journal:  Br J Haematol       Date:  2001-06       Impact factor: 6.998

4.  Patients with antiphospholipid antibodies and venous thrombosis should receive long term anticoagulant treatment.

Authors:  R H Derksen; P G de Groot; L Kater; H K Nieuwenhuis
Journal:  Ann Rheum Dis       Date:  1993-09       Impact factor: 19.103

5.  Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis.

Authors:  Paolo Prandoni; Anthonie W A Lensing; Andrea Piccioli; Enrico Bernardi; Paolo Simioni; Bruno Girolami; Antonio Marchiori; Paola Sabbion; Martin H Prins; Franco Noventa; Antonio Girolami
Journal:  Blood       Date:  2002-07-12       Impact factor: 22.113

6.  The management of thrombosis in the antiphospholipid-antibody syndrome.

Authors:  M A Khamashta; M J Cuadrado; F Mujic; N A Taub; B J Hunt; G R Hughes
Journal:  N Engl J Med       Date:  1995-04-13       Impact factor: 91.245

7.  Hereditary thrombophilia.

Authors:  Salwa Khan; Joseph D Dickerman
Journal:  Thromb J       Date:  2006-09-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.